13:30-13:45 Opening Remarks

Dr. Ahmi Ben Yehudah, Ministry of Health
Shay Rishoni, Prize4Life
Efrat Carmi, IsrAL.S

13:45-15:15 Session 1: Clinical research on ALS

- Dr. Marc Gotkine, Hadassah Medical Center, Hebrew University
  Relative Preservation of Finger Flexion in Amyotrophic Lateral Sclerosis

- Prof. Vivian Drori, Soraski Medical Center, Tel Aviv University
  Evaluation of routine laboratory tests as possible biomarkers of ALS in the preclinical and clinical phase

- Dr. Avi Gadot, Soraski Medical Center, Tel Aviv University
  Transglutaminase 6 antibodies in the serum of patients with ALS – is gluten-related sensitivity involved in motor neuron degeneration?

- Clara Weil, Maccabi Health Services
  Epidemiology of Amyotrophic Lateral Sclerosis in Israel (1997-2013)

- Dr. Yael Gofthel, BrainStorm Cell Therapeutics
  Transglutaminase 6 antibodies in the serum of patients with ALS – is gluten-related sensitivity involved in motor neuron degeneration?

- Dr. Avi Gadot, Soraski Medical Center, Tel Aviv University
  Relative Preservation of Finger Flexion in Amyotrophic Lateral Sclerosis

- Prof. Vivian Drori, Soraski Medical Center, Tel Aviv University
  Evaluation of routine laboratory tests as possible biomarkers of ALS in the preclinical and clinical phase

- Clara Weil, Maccabi Health Services
  Epidemiology of Amyotrophic Lateral Sclerosis in Israel (1997-2013)

- Dr. Yael Gofthel, BrainStorm Cell Therapeutics
  Transglutaminase 6 antibodies in the serum of patients with ALS – is gluten-related sensitivity involved in motor neuron degeneration?

- Clara Weil, Maccabi Health Services
  Epidemiology of Amyotrophic Lateral Sclerosis in Israel (1997-2013)

- Dr. Yael Gofthel, BrainStorm Cell Therapeutics
  Transglutaminase 6 antibodies in the serum of patients with ALS – is gluten-related sensitivity involved in motor neuron degeneration?

- Clara Weil, Maccabi Health Services
  Epidemiology of Amyotrophic Lateral Sclerosis in Israel (1997-2013)

- Dr. Yael Gofthel, BrainStorm Cell Therapeutics
  Transglutaminase 6 antibodies in the serum of patients with ALS – is gluten-related sensitivity involved in motor neuron degeneration?

15:15-15:30 Coffee break

15:30-17:15 Session 2: Novel targets for ALS therapy

- Prof. Michal Schwartz, The Weizmann Institute of Science
  Boosting autoimmunity activates the brain’s choroid plexus for leukocyte trafficking and alleviates disease pathology in a mouse model of ALS

- Prof. Beka Solomon, Tel Aviv University
  AMD3100: a small molecule for the treatment of ALS

- Prof. Chaya Brodie, Bar Ilan University
  Mesenchymal stem cells and their secreted targeted exosomes deliver exogenous miRNA to neural cells: Therapeutic impact in mice and in vitro models of ALS

- Dr. Michal Izrael, Kadimastem
  Cellular therapy of animal model of Amyotrophic Lateral Sclerosis by transplantation of human astrocytes derived from pluripotent stem cells

- Dr. Arie Gruzman, Bar Ilan University
  A novel chemical chaperone-based drug candidate for Amyotrophic Lateral Sclerosis (ALS)

- Prof. Daniel Offen, Tel Aviv University
  Gene therapy with neurotrophic factors rescue damaged motor neurons

- Dr. Eran Hornstein, The Weizmann Institute of Science
  microRNA dysregulation in ALS

- Prof. Miguel Weil, Tel Aviv University
  Multidisciplinary approach for drug development and treatment of ALS using drug high throughput screening and image based high content analysis on cells derived from ALS patients

17:00-17:30 Poster Session

17:30-19:30 Novel systems and insights on ALS pathology

- Dr. Eran Perlson, Tel Aviv University
  Microfluidic system for studying muscle-neuron communication and NMJ maintenance

- Prof. Ilana Gozes, Tel Aviv University
  Chromatin functions of TDP-43 are critical for its neuronal toxicity

- Dr. Amit Berson, University of Pennsylvania
  Chromatin functions of TDP-43 are critical for its neuronal toxicity

- Dr. Eliahu Heldman, Bar Ilan University
  Macrophage Migration Inhibitory Factor (MIF) as a Chaperone Inhibiting Accumulation of Misfolded SOD1

- Prof. Miguel Weil, Tel Aviv University
  Multidisciplinary approach for drug development and treatment of ALS using drug high throughput screening and image based high content analysis on cells derived from ALS patients

Scientific Committee:

Chairman: Prof. Daniel Offen, Tel Aviv University
Members of the committee:
Dr. Eran Perlson, The Weizmann Institute of Science
Dr. Adams Israelson, Ben Gurion University
Dr. Silvi Mandel, Teva
Dr. Neta Zach, Prize4Life